In cancer therapy, the combination of anti-CTLA4 and anti-PD-1 antibodies has demonstrated enhanced anti-tumor efficacy compared to monotherapy in various cancers, including melanoma and non-small-cell lung cancer [42,43]. This evidence concerns the gene CTLA4 and melanoma.